382 related articles for article (PubMed ID: 24941990)
1. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Bowles DW; McDermott JD; Jimeno A
Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Isaacsson Velho PH; Castro G; Chung CH
Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Schoppy DW; Sunwoo JB
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
Azoury SC; Gilmore RC; Shukla V
Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
[TBL] [Abstract][Full Text] [Related]
7. mTOR co-targeting strategies for head and neck cancer therapy.
Wang Z; Valera JC; Zhao X; Chen Q; Gutkind JS
Cancer Metastasis Rev; 2017 Sep; 36(3):491-502. PubMed ID: 28822012
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.
Hammerman PS; Hayes DN; Grandis JR
Cancer Discov; 2015 Mar; 5(3):239-44. PubMed ID: 25643909
[TBL] [Abstract][Full Text] [Related]
10. The promise of immunotherapy in head and neck squamous cell carcinoma.
Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
[TBL] [Abstract][Full Text] [Related]
11. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
12. Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma.
Isaacsson Velho PH; Castro G; Chung CH
Hematol Oncol Clin North Am; 2015 Dec; 29(6):993-1009. PubMed ID: 26568544
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma.
Sun Y; Wang Z; Qiu S; Wang R
Int J Biol Sci; 2021; 17(4):1104-1118. PubMed ID: 33867833
[TBL] [Abstract][Full Text] [Related]
14. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
15. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
16. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.
Ausoni S; Boscolo-Rizzo P; Singh B; Da Mosto MC; Spinato G; Tirelli G; Spinato R; Azzarello G
Cancer Metastasis Rev; 2016 Sep; 35(3):413-26. PubMed ID: 27194534
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
Tonlaar N; Galoforo S; Thibodeau BJ; Ahmed S; Wilson TG; Yumpo Cardenas P; Marples B; Wilson GD
Radiother Oncol; 2017 Sep; 124(3):504-512. PubMed ID: 28823407
[TBL] [Abstract][Full Text] [Related]
19. Targeted Therapy of Head and Neck Cancer.
Rieke DT; Klinghammer K; Keilholz U
Oncol Res Treat; 2016; 39(12):780-786. PubMed ID: 27889751
[TBL] [Abstract][Full Text] [Related]
20. The NOTCH Pathway in Head and Neck Squamous Cell Carcinoma.
Fukusumi T; Califano JA
J Dent Res; 2018 Jun; 97(6):645-653. PubMed ID: 29489439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
